Nat Lenzo, Anne Capp, Neel Patel, Michael Wheatcroft, David Cade. "CUPID (
            <sup>64</sup>
            Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592 targeted alpha therapy in prostate cancer.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e17023